Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
News|Articles|March 3, 2025
FDA updates in urology: February 2025
Author(s)Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month, key developments include advances in prostate and kidney cancer detection, as well as an emerging treatment option in primary hyperoxaluria 1 (PH1).
Related to this article
The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
This FAQ outlines key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Advertisement
Advertisement